Merrimack Pharmaceuticals Inc (NASDAQ:MACK), announced it will present clinical data on four novel antibody cancer therapeutics at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting, May 30-June 3, 2014 at McCormick Place in Chicago. Merrimack Pharmaceuticals Inc (NASDAQ:MACK), weekly performance is 9.87%. On last trading day company shares ended up $7.35. Analysts mean target price for the company is $13.80. Merrimack Pharmaceuticals Inc (NASDAQ:MACK), distance from 50-day simple moving average (SMA50) is 32.35%.
Inovio Pharmaceuticals Inc (NYSEMKT:INO), announced that at the Company’s Annual General Meeting held May 22, 2014, the Company’s shareholders approved the proposal of a reverse split of the Company’s common stock. The Company’s Board of Directors subsequently approved the immediate implementation of a 1-for-4 reverse stock split of Inovio’s common stock, where each 4 shares of issued and outstanding common stock and equivalents will be converted into 1 share of common stock. Following standard NYSE administrative processes, the Company plans to announce at a later time the effective date of the reverse split. Inovio Pharmaceuticals Inc (NYSEMKT:INO), advanced 5.26% in last trading session and ended the day on $2.20. INO, return on assets is -71.90%. Inovio Pharmaceuticals Inc (NYSEMKT:INO), quarterly performance is -31.68%.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)’s shares gained 3.80% to $69.71. The company presented at the UBS Global Healthcare Conference on Tuesday, May 20 at 11:00 a.m. ET. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), shares moved up 6.00% in last trading session and was closed at $71.18, while trading in range of $67.50 – 71.48. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), year to date (YTD) performance is -4.20%.
On May 08, 2014, Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), announced financial and operational results for the first quarter ended March 31, 2014. Total revenues for the first quarter of 2014 were $9.1 million, compared to $8.1 million for the first quarter of 2013. First quarter 2014 revenues included $1.7 million in Fanapt royalties received from Novartis as compared to royalties of $1.5 million for the first quarter of 2013. Licensing revenues recognized from the amortization of the$200.0 million upfront payment received from Novartis for Fanapt U.S. and Canadian rights were $7.5 million for the first quarter 2014, compared to $6.6 million for the first quarter of 2013. The higher amortization amount in the first quarter of 2014 resulted from a shortening of the expected patent life for Fanapt in the U.S. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), ended the last trading day at $10.44. Company weekly volatility is calculated as 6.80% and price to cash ratio as 3.52. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), showed a negative weekly performance of 5.88%.
On May 12, 2014, Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), reported its 1Q14 earnings for the quarter ended March 31, 2014. The company reported wider net loss for 1Q14 at $16.1 million ($0.17 per share) as compared to a net loss of $11.7 million ($0.14 per share) for 1Q13. The company reported cash equivalents, marketable securities and interest receivable at $144.7 million as at March 31, 2014. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), weekly performance is 7.06%. On last trading day company shares ended up $2.88. Analysts mean target price for the company is $5.44. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), distance from 50-day simple moving average (SMA50) is -4.22%.
Leave a Reply